VivoSeq
Oncology

Cutaneous T-Cell Lymphoma

73

Pipeline Programs↗

9

Active Trials↗

42

Companies Involved↗

Cutaneous T-cell lymphoma is a moderately active landscape with 73 programs across 42 companies. The most active players are TetraLogic Pharmaceuticals, Innate Pharma, Jiangsu Simcere Pharmaceutical Co., Ltd.. 12 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

65/100

Pipeline Velocity

19/100

Mech. Concentration

10/100

Completion Rate

71/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

TetraLogic Pharmaceuticals

1 program

Phase 1I

Innate Pharma

1 program

Phase 1Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.

1 program

Phase 1M

Moleculin Biotech, Inc.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical3

Denileukin Diftitox

Eisai

Valchlor

Helsinn Therapeutics (U.S.), Inc

Comparator: Pbo

Merck & Co.

Phase 116

Pralatrexate

Acrotech Biopharma Inc.

Durvalumab

AstraZeneca

Carfilzomib

Virionyx Corporation Limited

Carmustine

Melissa K Accordino

LBH589

Novartis

Phase 236

Curcumin

Merck & Co.

Romidepsin

Teva

Sintilimab

Innovent Biologics (Suzhou) Co. Ltd.

Enzastaurin

Eli Lilly

Panobinostat

SecuraBio

Phase 36

Brentuximab Vedotin

Pfizer

Mogamulizumab

Kyowa Kirin, Inc.

Vorinostat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Humax-CD4

Genmab

E7777

Eisai

Approved12

Venetoclax

AbbVie

Bexarotene

Bausch Health Americas, Inc.

Belinostat

Acrotech Biopharma Inc.

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Imiquimod

Bausch Health Americas, Inc.

Analysis

Modality Breakdown

88%

Small molecule

64 of 73 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody68%Antibody–drug conjugate11%Protein / enzyme11%Radiopharmaceutical11%

Small molecule leads; the ring shows all 73 classified programs, each share of the total. Modality classified for 98% of 83 pipeline programs.

Analysis

Trial Status

86

clinical trials

Completed49 · 57%
Terminated14 · 16%
Unknown status7 · 8%
Withdrawn6 · 7%
Recruiting4 · 5%
Not yet recruiting3 · 3%
Other3 · 3%

Clinical Trials

Trial Activity

86 trials

Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma
Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT04128072·43 enrolled
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT07047885·38 enrolled
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT05956041·23 enrolled
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06698822·20 enrolled
A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)
Active, not recruiting·UUniversity College, London·Phase 2·NCT03385226·46 enrolled
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Active, not recruiting·CChengdu Zenitar Biomedical Technology Co., Ltd·Phase 2·NCT06485219·50 enrolled
Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT07178457·84 enrolled
A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT07213882·30 enrolled
Evaluation of the Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma
Not yet recruiting·PPeking University First Hospital·Phase 2·NCT07658924·35 enrolled
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
Completed·National Cancer Institute (NCI)·Phase 1·NCT00001249·30 enrolled
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00506129·33 enrolled
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Completed·HHelsinn Therapeutics (U.S.), Inc·N/A·NCT02296164·300 enrolled
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
Completed·Eisai logoEisai·Phase 4·NCT00050999·195 enrolled
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Completed·Eisai logoEisai·Phase 2·NCT02676778·45 enrolled
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Completed·FFox Chase Cancer Center·Phase 1·NCT02616965·16 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)